



## **Theratechnologies Obtains U.S. Patent Term Extension for Tesamorelin**

June 10, 2014

**Montreal, Canada – June 9, 2014** —Theratechnologies Inc. (TSX: TH) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent term extension certificate for tesamorelin, the Company's principal compound. Pursuant to this certificate, the USPTO has extended the term of US patent No. 5,861,379 (tesamorelin composition of matter patent) by five years. This patent was originally set to expire in May 2015 and is now set to expire in May 2020.